Osteopontin as a Novel Biomarker for the Prognosis and Clinical Pathology of Prostate Cancer: A Systematic Review and Meta-Analysis

Abstract

Background: Evaluation of the feasibility for osteopontin (OPN) to serve as a biomarker in the prognosis and clinical pathological features of prostate cancer patients.Methods: The original publications related to osteopontin and prostate cancer were comprehensively searched in the online databases, including PubMed, Embase, Cochrane Library, Web of Science, Medline, Wanfang database and China National Knowledge Infrastructure up to August 2019. Results were analyzed by software Revman 5.3 and Stata 12.0. Results: A total of 21 studies were included in the analysis and the result showed that the positive OPN expression group had a lower overall survival than the negative expression group (univariate: HR=2.32, 95%CI [1.74, 3.10], multivariate: HR=2.41, 95%CI [1.63, 3.57]) and a lower biochemical relapse-free survival than the negative group (univariate: HR=1.42, 95%CI [0.92, 2.17], multivariate: HR=1.61, 95%CI [1.39, 1.87]). In addition, there was a higher expression level of OPN in prostate cancer tissues than in normal prostate tissues (OR=46.55, 95%CI [12.85, 168.59], p<0.00001) and benign prostatic hyperplasia tissues (OR=11.07, 95%CI [3.43, 35.75], p<0.0001). Moreover, OPN positive expression was also related to high Gleason score (OR=2.64, 95%CI [1.49, 4.70], p=0.0009), high TNM stage (OR=3.15, 95%CI [1.60, 6.20, p=0.0009), high Whitmore-Jewett stage (OR=2.53, 95%CI [1.06, 6.03], p=0.04), high lymph node (OR=3.69, 95%CI [1.88, 7.23], p=0.0001), and distant metastasis (OR=8.10, 95%CI [2.94, 22.35], p=0.01). There was no difference observed in the differentiation of prostate cancer (OR=1.79, 95%CI [0.39, 8.33], p=0.46).Conclusion: Osteopontin could be recognized as a promising novel diagnostic and prognostic biomarker for prostate cancer patients.

Is Osteopontin a Good Marker for Bone Metastasis in Canine Mammary Gland Tumor and Prostate Cancer?

“…In previous studies, increased OPN expression has been implicated in the malignant transformation of prostate epithelial cells, tumor progression [16] and patient survival [32]. In the present study, we reported higher OPN expression in samples from primary tumors with bone metastasis than in those lacking metastases, supporting the role of this protein in cancer cell progression, which is in agreement with human studies [16,35]. Our findings are similar to those reported by Kim et al [36] and Bramwell et al [15], who showed that human patients with metastatic cancer have higher circulating levels of OPN and tumors that are more likely to metastasize.…”

“…For instance, Tan et al [38] demonstrated that high OPN expression in breast cancer cells promotes tumor growth and invasiveness. In PC, OPN plays a critical role in the development of castration-resistant diseases that are particularly challenging to treat [35]. However, more research is needed to fully understand the molecular mechanisms underlying the role of OPN in breast and PC and to develop effective OPN-targeted therapies.…”